It appears all the structural changes are in place.
New leadership team.
investigation complete.
RSU for employee incentives complete.
Focus on wearables.
Looking for Ryan and Ian to set the direction, with "integrity and clarity."
Cost structure has been greatly reduced.
Need update on programs, production, supply contracts, new customers and the status on the syringe business.
Update on AbbVie and Flextronics, patents and Imperium.
Nasdaq compliance plan submitted.
Need earnings call. ( will 3rd and 4th quarter calls be combined?)